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Although the advantages of early infant HIV diagnosis and treatment initiation are well established, children often present late to
HIV programs in resource-limited settings. We aimed to assess factors related to the timing of treatment initiation among HIV-
infected children attending three clinical sites in Uganda. Clinical and demographic determinants associated with early disease
(WHO clinical stages 1-2) or late disease (stages 3-4) stage at presentation were assessed using multilevel logistic regression.
Additionally,semistructuredinterviewswithcaregiversandhealthworkerswereconductedtoqualitativelyexploredeterminantsof
latediseasestageatpresentation.Of306childreninitiatingﬁrst-lineregimens,72%presentedlate.Riskfactorsforlatepresentation
were age below 2 years old (OR2.83, P = 0.014), living without parents (OR3.93, P = 0.002), unemployment of the caregiver
(OR4.26, P = 0.001), lack of perinatal HIV prophylaxis (OR5.66, P = 0.028), and high transportation costs to the clinic (OR2.51,
P = 0.072). Forty-nine interviews were conducted, conﬁrming the identiﬁed risk factors and additionally pointing to inconsistent
referral from perinatal care, caregivers’ unawareness of HIV symptoms, fear, and stigma as important barriers. The problem of late
disease at presentation requires a multifactorial approach, addressing both health system and individual-level factors.
1.Introduction
Despite the eﬀectiveness of antiretroviral prophylaxis for
the prevention of mother-to-child transmission (PMTCT) of
HIV, approximately 370,000 children were newly infected
with HIV in 2009. An estimated 2.5 million children are cur-
rently infected with HIV worldwide, of whom 2.3 million
reside in sub-Sahara Africa [1]. HIV infected infants have
much higher rates of disease progression and mortality
than adults or older children, even with a relatively high
percentage of CD4 T lymphocytes [2, 3]. Without treatment,
over 50% of HIV-infected children are estimated to die
before the age of two [4].
Despitetheincreasedmortalityinyounginfants,children
in resource-limited settings generally initiate ART at an old-
er age and with advanced disease [4, 5]. In 2008, the CHER
trial in South Africa demonstrated a 76% mortality reduc-
tion among infants in whom antiretroviral treatment (ART)2 AIDS Research and Treatment
Table 1: Characteristics of the Joint Clinical Research Centre (JCRC) sites.
Kampala Fort Portal Mbale
Location National capital District capital District capital
Populationa 1,659,600 47,100 91,800
Catchment area Urban Urban and rural Urban and rural
HIV prevalenceb 5–9.9% 5–9.9% 5–9.9%
Number of adults in care at JCRC (% of total)c 15306 (85.7) 5880 (87.3) 3027 (85.7)
Number of children in care at JCRC (% total)c 2553 (14.3) 858 (12.7) 506 (14.3)
Number of adults receiving ART at JCRC (% of adults in care)c 6096 (39.8) 2575 (43.8) 2505 (82.8)
Number of children receiving ART at JCRC (% of children in care)c 888 (34.8) 340 (39.6) 349 (69.0)
aSource: Uganda Bureau of Statistics (UBOS) 2011.
bSource: UNAIDS Epidemiological Factsheet Uganda 2009.
cSource: Monitoring and Evaluation records at JCRC, 2011.
was initiated before 12 weeks of age, regardless of HIV
symptomsorimmunodeﬁciency,comparedwiththosedefer-
ring therapy [6]. Based on these important ﬁndings, the
World Health Organization (WHO) guidelines currently re-
commendthatallHIV-infectedchildrenundertheageoftwo
should initiate treatment [7]. The WHO estimates that only
32% of HIV-infected children in East Africa requiring ART
are currently treated [8].
Although government policies and eﬀorts by interna-
tional donors seek to make antiretrovirals (ARVs) freely
available to children through national ART programs, other
factors are holding back further scale-up of pediatric ART in
Africa. A wide array of such factors or barriers has been put
forwardin theliteratureincluding healthsystemand person-
al level barriers [9, 10]. The development of new strategies to
overcomethesebarriersisessentialtoreducechildmorbidity
and mortality, thereby contributing to the achievement of
the Millennium Development Goal 4 [11]. However, limited
structured research has been performed and there is little
setting-speciﬁc insight into health care barriers.
The Joint Clinical Research Centre (JCRC) is a main pro-
vider of HIV care and treatment in Uganda. It was founded
in 1990 as a strategic partnership with the Ministry of Health
and Makerere University Medical School. The national JCRC
network—consisting of more than 50 clinical sites—has over
20 years of experience with ART, from conducting clinical
trials to nationwide roll-out programs since 2003. This study
describes the characteristics of children initiating HIV care
at three JCRC clinical sites based in Kampala, Fort Portal,
and Mbale. Drawing on both quantitative and qualitative
datasources,weaimedtoidentifythemostimportantfactors
inﬂuencing the timing of pediatric ART initiation.
2. Methods
2.1. Population,Setting, andStudy Design. We used an obser-
vational study design with a mixed methodology. This al-
lowed us to triangulate ﬁndings from both participants and
methods and generate a deeper understanding of the barriers
toinitiationofpediatricHIVcare.Thepresentstudywasper-
formedaspartoftheMonitoringAntiretroviralResistancein
Children (MARCH) observational cohort, monitoring HIV-
infected children (below 12 years old) initiating ART at
three JCRC sites. The clinical sites in Kampala, Fort Portal,
and Mbale are Regional Centers of Excellence and provide
ART for both adult and pediatric patients. The Kampala
site, based in the national capital, houses JCRC headquarters
and mainly serves an urban population. The sites in Fort
Portal and Mbale are located in district capitals, serving the
Rwenzori region in Western Uganda and the entire Eastern
region of Uganda, respectively [12]. People attending these
two clinical sites come from both urban and rural areas
(Table 1).
The sample size was calculated based on the MARCH
study objective to monitor HIV drug resistance. This cross-
sectional, observational substudy aims to identify the most
important factors inﬂuencing the timing of pediatric ART
initiation at the three sites. Potential participants were in-
formed of the study and screened for eligibility by the study
staﬀ at each clinic. All children that initiated ART were
included; previous use of ARVs for the purpose of therapy
(i.e., ART or mono/duo therapy) was an exclusion cri-
terion. Previous use of ARVs for PMTCT was allowed. The
ethical committees of JCRC and the Academic Medical Cen-
ter of the University of Amsterdam approved the study pro-
tocol. The parent(s)/guardian(s) of all eligible children pro-
vided written informed consent. Children above the age of
eight who were aware of their HIV status provided written
informed assent. Routine sociodemographic, clinical, and
laboratory data were collected using electronic case report
forms, which were aggregated in a web-based data system.
Whenever possible, the health status and medication use of
the mother were also captured.
2.2. Quantitative Methods. Group comparisons for categor-
ical data were performed using the chi-square test and for
continuous data using Student’s t-test. Nutritional status was
assessed by means of the WHO Child Growth Standards:
WHO Anthro version 3.2.2 (age 0–5) and WHO Reference
2007forheightandweight(age5–19)[13,14].Severeimmu-
nodeﬁciencywasclassiﬁedaccordingtotheWHOguidelines:
CD4cellpercentage<25%orCD4cellcount<1500cps/mm3
below 12 months old; CD4 cell percentage <20% or CD4 cell
count <750cps/mm3 between 12 and 35 months old; CD4
cellpercentage<15%orCD4cellcount<350cps/mm3 above
35 months old [15]. WHO clinical staging was used to deﬁneAIDS Research and Treatment 3
early disease stage or late disease stage at presentation: chil-
dren in stage 1 (asymptomatic) or 2 (mild symptoms) were
considered to have early disease stage, and children in stage
3 (advanced symptoms) or 4 (severe symptoms) were con-
sidered to have late disease stage [16].
Multivariate logistic regression analysis with random in-
tercepts was used to examine risk factors for late disease
stage at presentation, while accounting for clustering of ob-
servations within sites. Results are expressed as odds ratios
(ORs)with95%conﬁdenceintervals(CIs)andP values,with
two-sided P values < 0.05 considered statistically signiﬁcant.
A sensitivity analysis was performed, excluding children
with unknown source of HIV infection. All analyses were
performed with Stata version 10 (StataCorp LP, TX, USA).
2.3. Qualitative Methods. Qualitative semistructured inter-
views with both JCRC health workers and caregivers of
children attending JCRC clinical sites were conducted to
explore participants’ views of key ﬁndings from the quan-
titative results, such as the late (disease stage) presentation of
children for ART. Interviews consisted of open-ended ques-
tions to explore perceived barriers to ART initiation. Topics
covered in the interview were the referral system, quality
of care, HIV testing and treatment protocols, characteristics
of the caregiver, transport to the clinic, and pharmacy and
laboratory facilities. Pilot interviews were held with three
local physicians; questions were adapted if necessary to
ensure that they were appropriate for all participants. A
separate questionnaire aimed at health workers, testing ART
guideline knowledge, was developed in collaboration with a
pediatric infectious disease specialist.
Interviews were conducted by the ﬁrst author (TSB) in
July 2011 at the three clinical sites. All caregivers of children
below 12 years of age were identiﬁed by the doctor or coun-
selor during a regular follow-up visit. Data were collected
until the saturation point [17] was reached; we are therefore
conﬁdent that the ﬁndings presented are internally valid. All
healthworkers—pediatricians,clinicians,nurses,counselors,
and adherence oﬃc e r s — i n v o l v e di np e d i a t r i cH I Vc a r ea t
JCRC were interviewed at all 3 clinics, to maximize health
worker representation and internal validity.
All interviews took place in private settings where oth-
er people could not hear the respondents’ answers. For in-
terviews with caregivers, a local trained counselor assisted
with translation and/or interpretation of questions. Inter-
views were recorded and transcribed in English. Using the
framework approach for qualitative analysis [17], key issues
and themes emerging from the data were identiﬁed, and
responseswerecomparedandcontrastedamongthediﬀerent
groups of study participants. Findings from the qualitative
study were interpreted using Andersen’s Behavioral Model of
Health Services Use [18–20].
3. Results
3.1. Quantitative Results
3.1.1. Participant Characteristics. Between January 2010 and
May 2011, 310 children initiating ﬁrst-line ART were
enrolled in the MARCH study (92 from Kampala, 113
from Fort Portal, and 105 from Mbale). After excluding a
protocol violation (n = 1) and children with missing data on
eligibility criteria (n = 3), 306 participants were included
in the analysis. The median age was 4.8 years and 50%
(n = 152) were boys (Table 2) .T h er e p o r t e ds o u r c eo fH I V
infection was mother-to-child transmission (MTCT) in 284
(93%) participants. In 22 (7%) children, the source of in-
fection was unknown. HIV-status was known for 208 (68%)
of their mothers, of whom 195 (94%) were HIV infected, 1
(0.5%) was uninfected, and 12 (6%) were unaware of their
HIV status. Among the HIV infected mothers, 45% were on
ART, 49% were not on ART, and for the remainder ART
usage was unknown.
At ﬁrst presentation, 72% of participants were in WHO
clinical stage 3 or 4 (40% in Kampala, 82% in Fort Portal,
and 90% in Mbale). Severe immunodeﬁciency according to
a decreased CD4 cell count-for-age was present in 31% of
children and in 51% when based on CD4 cell percentage-
for-age. Severe immunodeﬁciency was more prevalent in
KampalacomparedtoFortPortalandMbale(Table 2).There
was a poor correlation between clinical staging and im-
munological status: of children in clinical stage 3 or 4, 47%
also had severe immunodeﬁciency according to CD4 cell
percentage-for-age.
Inchildrenbelow5yearsofage,theprevalenceofweight-
for-age z-score < −2 standard deviation (SD) was 43%;
height-for-age z-score < −2SD was found in 62% (Table 3).
Of children in clinical stage 3 or 4, 70% had HIV-related
malnutrition.Thenutritionalstatusofchildrendidnotdiﬀer
signiﬁcantly between the clinical sites.
3.1.2. Risk Factors for Late Disease Stage at Presentation:
Quantitative Results. Compared to children with early dis-
ease stage at presentation, children with late disease stage
at presentation were more likely to be younger, to have an
unemployed caregiver, and to have higher transportation
costs. They were less likely to be living with both parents or
to have a history of uptake of PMTCT services (Table 4). Late
disease stage at presentation was not associated with sex, the
caregiver’s health status or education, transportation time,
time between HIV-positive diagnosis and ART initiation, or
waiting time at the clinic. The sensitivity analysis, excluding
22 children in whom MTCT was not conﬁrmed, yielded
similar associations (data not shown).
3.2. Qualitative Results
3.2.1. Participant Characteristics. Interviews were conducted
with 19 health workers and 30 caregivers. Twenty-one car-
egivers were HIV infected, six were uninfected, and three
reported they were unaware of their status. Among the HIV-
infected caregivers, sixteen caregivers were in care at JCRC
and the remaining caregivers were in care at another clinic.
Five health workers were specialized pediatricians; others
were clinicians (n = 2), nurses (n = 6), counselors (n = 4),
or adherence oﬃcers (n = 2) with pediatric training.
The caregivers included those of children participating in
the MARCH study and those of other clinic attendants aged4 AIDS Research and Treatment
Table 2: Clinical and demographic characteristics of the “Monitoring of Antiretroviral Therapy in Children” cohort participants.
Overall Study site P value
n = 306 (100) Kampala
n = 91 (29.7)
Fort Portal
n = 112 (36.6)
Mbale
n = 103 (33.7)
Sex Male 152 (49.8) 43 (47.3) 55 (49.1) 54 (52.9) 0.719
Age, median years (IQR) 4.8 (2.2–8.6) 4.0 (1.5–8.5) 4.2 (1.9–8.5) 5.8 (3.0–8.7) 0.127
Age groups
<2 years old 76 (24.8) 32 (35.2) 29 (25.9) 15 (14.6) 0.005
2–5 years old 84 (27.5) 18 (19.8) 37 (33.0) 29 (28.2)
5–12 years old 146 (47.7) 41 (45.1) 46 (41.1) 59 (57.3)
Age at (ﬁrst) conﬁrmed
HIV+ test Median (IQR) 3.7 (1.6–6.8) 3.0 (1.3–7.2) 3.3 (1.1–6.8) 4.5 (2.7–6.8) 0.264
WHO clinical stage Stages 3 and 4 221 (72.2) 36 (39.6) 92 (82.1) 93 (90.3) <0.001
HIV-TB coinfection Pulmonary tuberculosis 31 (10.1) 18 (19.8) 6 (5.4) 7 (6.8) 0.001
Severe immunodeﬁciencya CD4 count-for-age 67 (31.0) 36 (40.0) 9 (21.4) 22 (26.2) 0.047
CD4 %-for-age 102 (51.3) 57 (63.3) 18 (42.9) 27 (40.3) 0.008
Viral load, median
log10 cps/mL (IQR)c 5.0 (4.4–5.5) 5.2 (4.7–5.6) 5.1 (4.2–5.5) 4.7 (4.1–5.3) 0.001
Main reason for ART
initiationd
HIV diagnosis <24 months 30 (9.8) 20 (22.0) 9 (8.0) 1 (1.0) <0.001
Immunological status 102 (33.3) 55 (61.4) 25 (22.3) 22 (21.4)
WHO clinical stage 174 (56.9) 16 (17.6) 78 (69.6) 80 (77.7)
Time between HIV test and
ART initiation, median
days (IQR)
<2 years old 43 (19–85) 40 (18–66) 48 (23–103) 43 (26–86) 0.299
2–5 years old 97 (26–400) 117 (34–309) 197 (29–546) 64 (15–180) 0.302
5–12 years old 258 (29–802) 242 (28–634) 296 (35–757) 216 (21–848) 0.474
PMTCT exposed Yes 14 (4.6) 11 (12.1) 3 (2.7) — <0.001
Drugs for PMTCT
Single dose NVP 9 (2.9) 6 (6.6) 3 (2.7) — 0.025
NVP 4 (1.3) 4 (4.4) — — 0.008
AZT 2 (0.7) 2 (2.2) — — 0.093
Unknown 1 (0.3) 1 (1.1) — — 0.306
Breastfeeding Yes 24 (7.9) 10 (11.1) 12 (10.7) 2 (1.9) 0.023
“Is there enough food in
the household?” Yes 300 (98.0) 87 (95.6) 110 (98.2) 103 (100.0) 0.087
Data are presented as n (%) unless otherwise indicated.
aSevere immunodeﬁciency, deﬁned as CD4 percentage < 25% or CD4 count < 1500cps/mm3 b e l o w1 2m o n t h so l d ,C D 4p e r c e n t a g e< 20% or CD4 count <
750cps/mm3 between 12 and 35 months old, and CD4 percentage <15% or CD4 count < 350cps/mm3 above 35 months old.
bCD4 count based on n = 218; CD4 percentage based on n = 201.
cViral load based on n = 184.
dMain reason for initiation as indicated by clinician.
0–12 years old. All but four adults accompanying a child to
the clinic were the primary caregivers. The caregivers were
mostly self-employed; six were unemployed.
3.2.2. Health System Factors: Resources and Organization.
Kampala is the only site with a separate pediatric outpatient
clinic. All sites have access to local laboratory facilities
(including HIV-DNA PCR testing for infants <18 months
of age), ﬁrst- and second-line ARVs, and ready-to-use
therapeutic food products (i.e., Plumpy’nut). According to
the physician respondents, the clinic’s capital and labor
resources are suﬃcient to take care of all children attending
the clinic. Occasional stock-outs of speciﬁc drugs or ﬁxed-
dose combinations were reported, in which case drugs are
borrowed from other clinics or doctors prescribe diﬀerent
formulations to reconstruct the same regimen. When phar-
macy stocks are low, ARV prescriptions are given for one
month at a time rather than the regular three months.
All doctors were aware that ART should be initiated in
infants below the age of two years, irrespective of CD4 count
or clinical condition. The general consensus among health
workers was that enough qualiﬁed personnel are available at
the clinic, although the workload is high. There was often
insuﬃcient time for thorough counseling, which can result
in longer waiting times for patients and caregivers attending
the clinic. Health workers evaluated the pediatric HIV care
delivered at JCRC as better in comparison to other clinics.
However, health workers also noted that it is necessary to
spread information about the clinic in the community.
When we sit here and wait for people to come, we
can wait for a long time. We have to go out there
and tell about the available services so they can
choose to come.
Female counselor, Mbale.AIDS Research and Treatment 5
Table 3: Nutritional status of the “Monitoring of Antiretroviral
Therapy in Children” cohort participants at presentation.
n = 306
Underweight
(WAZ < −2SD)
<5 years old 42.7 (34.6–50.7)
5–12 years old 24.5 (15.2–33.7)
Severe underweight
(WAZ < −3SD)
<5 years old 26.1 (18.9–33.3)
5–12 years old 12.8 (5.5–20.0)
Stunting
(HAZ < −2SD)
<5 years old 62.0 (53.9–70.1)
5–12 years old 39.0 (30.4–47.5)
Severe stunting
(HAZ < −3SD)
<5 years old 40.0 (31.8–48.2)
5–12 years old 18.4 (11.5–25.3)
Wasting
(WHZ < −2SD)
<5 years old 21.7 (14.9–28.4)
5–12 years old NA
Severe wasting
(WHZ < −3SD)
<5 years old 7.0 (2.7–11.3)
5–12 years old NA
BMI-for-age z-score
(< −2SD)
<5 years old 16.3 (10.2–22.3)
5–12 years old 8.6 (3.6–13.7)
Midupper arm
circumference n (%)a ≤13.5cm 55 (37.9)
Data are presented as percentage with 95% conﬁdence interval (CI) unless
otherwise indicated. No signiﬁcant diﬀerences were found between clinical
sites. Reference data used are WHO Anthro version 3.2.2, January 2011 for
age 0–5 and Reference 2007 for age 5–19 [13, 14, 21]. 33 z-scores were
excluded from analysis because of biological implausibility (WAZ n = 9,
HAZ n = 19, WHZ n = 3, and BMI-for-age n = 2).
aMidupper arm circumference only applicable for children 1–5 years old
(n = 148). WAZ: weight-for-age z- s c o r e ,H A Z :h e i g h t - f o r - a g ez-score,
WHZ: weight-for-height z-score, and BMI: body mass index (in kg/m2).
Health workers reported that many children are referred
to JCRC after visiting private clinics, local hospitals, and
sometimes traditional healers or herbalists for recurrent in-
fections.Therearenoantenatalcare(ANC)servicesatJCRC,
and therefore only HIV-infected pregnant women who are
already attending the JCRC adult clinic are immediately
linkedwithpediatriccare.ReferralfromexternalANCclinics
is limited. In Fort Portal, the regional general hospital
oﬀering ANC is adjacent to the JCRC clinic, which facilitates
referral of HIV-infected pregnant women.
Family-centered care is not routinely oﬀered at JCRC,
but health workers encourage parents to bring their other
children and family members. Disclosure issues play a role
as health workers construct a family tree of the HIV status of
the family members and ask to bring in any children with
unknown status. When children and caregivers come for
HIV testing, they receive a ticket with a number to match
their test results. By using this method, people are assured
of anonymous testing, thereby reducing fear of disclosure.
Health workers’ recommendations for improving access to
care are listed in the Box 1 .
3.2.3. Population Factors: Living Situation and Transport.
Both health workers and caregivers reported that children
without parents are living under poorer conditions and
present later in care. When the mother is receiving HIV care,
the child is more likely to present early. The eﬀect of living
in an institution (e.g., orphanage) can go both ways. Some
institutions bring their children early because they recognize
the importance of HIV testing and can provide transport;
others have fewer resources and do not prioritize HIV
testing. Health workers pointed out that caregivers’ ﬁnancial
constraints and lack of employment are important barriers
to access health care. More highly educated caregivers seem
to visit earlier, but taking time oﬀ w o r kc a nb ea no b s t a c l e .
Some caregivers fear to disclose to their employers, and thus
have a hard time justifying their absence to attend clinic
visits. The unemployed have more time, but lack the money
to visit the clinical sites.
When the caregiver is employed, they have the ad-
vantage of money for transport, but they can be
too busy at work to come. For the unemployed it is
diﬃcult to pay for transport.
Female counselor, Fort Portal.
Transportation costs are prohibitively high when consid-
ered in comparison to the need for food. Furthermore,
having to travel long distances to reach the clinic makes it
diﬃcult for people to leave and return home within one day,
especially when no or limited public transport is available.
This problem was more frequently reported in Fort Portal
and Mbale compared to Kampala.
To some people transportation costs matter. For
the ones living in the villages; they do not have the
income, but they do have time.
HIV-positive mother of a ﬁve-year-old boy, Fort
Portal.
Mydaughterlivedinthevillagesanditwastoofar
f o rh er .T h a ti swh yIa mt a k i n gc a r eo fh erd a u gh -
ter now. The mother is dead now. Just being a
housewife, raising money for transport is hard.
HIV-negative grandmother of a ten-year-old
girl, Mbale.
3.2.4. Population Factors: Knowledge, Stigma, and Fear. Ac-
cording to health workers, many women are delivered by
traditionalbirthattendantsandarenottestedforHIVduring
pregnancy. This increases the likelihood that a child’s in-
fection remains unnoticed; the child may only be tested
after becoming clinically ill or after the loss of one or both
parents. Caregivers have often visited other clinics for the
child’s frequent infections before enrolling at the JCRC clin-
ic. Health workers described that health-seeking behavior
among caregivers can be delayed due to lack of knowledge or
denial of HIV symptoms. Caregivers also reported that HIV
is something people do not think about or do not want to
thinkabout.Theyareoftennotreadytodisclosetheirortheir
child’s HIV status to others. Health workers recommended
involving men more actively in ANC, in order to improve the
uptake of PMTCT measures and enrolment of HIV-exposed
children in pediatric HIV care.
Men need more involvement, include men to
PMTCT, now only very few come. They are the
biggest decision makers in the home. This would
strengthen adherence too.
Female pediatric counselor, Fort Portal.6 AIDS Research and Treatment
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(i) Improve antenatal care attendance and linkage to ART clinics.
(ii) Involve men during antenatal care.
(iii) Increase awareness of care and treatment services.
(iv) Improve community outreach for HIV testing.
(v) Facilitate transport to clinics.
Box 1: Health workers’ recommendations to improve timely access to ART for children.
Healthworkersexplainedthatsensitizationcampaignsby
means of radio and advertisements were helpful to spread
information about HIV prevention and care and decrease
stigma. At the same time, they acknowledge that stigma
experienced by caregivers remains an important barrier to
care.
H I Vi sn o tat a b o oa n ym o r e .T h er eu se dt ob eal o t
of stigma, in the ’90 and early ’00. There’s been a
lotofsensitizationforHIV.Youseemoreandmore
people test and seek care.
Male doctor, Mbale.
HIV is not a taboo anymore, but there’s stigma.
People do not want to associate with HIV. They
fear to come to the clinic because someone might
see them, which aﬀects adherence. Stigma also
delays the start of ART.
Female counselor, Fort Portal.
Fearwasamajorfactorreportedbycaregiversasabarrier
to visiting ART clinics. People fear to be seen at the clinic
and fear that other people get to learn about their HIV
status. Fear of disclosure appeared to be more common in
the smaller towns compared to the city, as evidenced by the
responses from both health workers and caregivers.
I never got married and feared to tell my mother.
She is harsh and will tell everybody to stigmatize
me. Nobody knows about my and my daughter’s
HIV status. They discriminate you, even at work.
HIV-positive mother of a three-year-old girl,
Mbale.
4. Discussion
This mixed-method study examined factors inﬂuencing the
timing of ART initiation among children attending HIV
clinics in Uganda. Even though ART is now free and widely
available in Uganda, 72% of the children in this study
presentedwithadvancedHIVdiseaseattheirinitialvisit.The
main risk factors for this late disease stage at presentation
identiﬁed in our study—from both quantitative and qual-
itative data—included lack of HIV-speciﬁc perinatal care,
living without parents, ﬁnancial constraints of the caregiver,
caregivers’ unawareness of HIV symptoms, stigma, and fear.
Our study adds insight into the challenges of identifying
HIV-infected infants and children sooner and recruiting
them into care. In the setting of the JCRC network of HIV
treatment sites in Uganda, linkage to the ANC systems and
psychosocial support are recognized as priorities to improve
pediatric access. Even though JCRC sites are at the high-end
with respect to resources, infrastructure, staﬀ, and available
diagnostics, late disease stage at presentation was a frequent
and important problem among children initiating ART. The
barriersidentiﬁedinourstudyarethereforelikelyofnational
relevance and applicable to other HIV clinics in Uganda.
4.1. Health System Factors. The linkage between ANC and
pediatric ART clinics was found to be inconsistent. This lack
of coordination across services is similar to previous studies
investigating barriers to timely pediatric ART initiation in
resource-limited settings [22, 23]. Failure to diagnose HIV in
pregnancy, to provide PMTCT services, and to followup the
HIV-exposed infant represent missed chances for prevention
of HIV transmission. As previous research has also shown,
integrating antenatal services, PMTCT, early infant diagno-
sis, and pediatric HIV care greatly improves outcomes for
HIV-infected infants in resource-limited settings [24–28].
As ANC is not performed at JCRC, this challenge
could be addressed by closer collaboration between JCRC
Centers of Excellence and outside ANC providers. HIV-
infected women should be routinely referred to have their
infants tested after delivery and actively followedup to
ensure they receive the results. Health workers at JCRC have
suggested collaborating with traditional birth attendants
to reach women who do not visit regular ANC service
centers. Additionally, improving male involvement in ANC
was proposed as men could be decision-makers in seeking
care for the child. Studies have shown that male attendance
in ANC is a cost-eﬀective strategy to increase PMTCT uptake
and is associated with reduced MTCT and infant mortality
[29–31].
We examined the time between HIV test and ART
initiation and found that it was increased in older children.
It is possible that the ﬁrst HIV-positive test was performed
outside of JCRC, with a subsequent referral delay for ART
initiation. Secondly, children might have been tested at
JCRC in early disease stage and started ART later when
immunological or WHO stage criteria were met. This is in
line with the high numbers of children in care at JCRC in
whom ART is not yet initiated (Table 1). Regression analysis
showed that lag time between the ﬁrst HIV diagnosis and
ARTinitiationwasnotasigniﬁcantriskfactorforlatedisease
stage at presentation.
Although the clinics in Fort Portal and Mbale have
similar resources as the Kampala clinic, the latter was found
to have a higher percentage of early disease stage presenters.
The clinic urban setting likely contributes to improved
accessibility, and stigma was reported less frequently in8 AIDS Research and Treatment
the qualitative study compared to the other sites. Health
workers at all JCRC clinics were well trained and consistently
adhered to current pediatric HIV guidelines. The clinics
could give more attention to community outreach and active
case ﬁnding in order to increase parents’ awareness and to
identifyHIV-infectedchildrenbeforetheonsetofsymptoms.
Community outreach could be targeted speciﬁcally at the
most vulnerable children, such as those in orphanages.
Alternatively, outreach could be performed by screening
infants at immunization clinics [32].
Rates of underweight and stunted children were alarm-
ingly high, which concurs with previous reports among
HIV-infected children in Uganda [33, 34]. Malnutrition was
a common clinical stage 3 or 4 deﬁning symptom, and
therefore timely referral to HIV care is perhaps the most
critical nutritional intervention. JCRC routinely provides
therapeutic foods. Additionally, nutritional education for
caregivers and suﬃcient supply of micronutrients are impor-
tant to decrease rates of underweight and stunting [35].
4.2. Population Factors. When examining individual-level
barriers to care, the child’s living situation was found to
be an important determinant. This corresponds with earlier
studies in which orphans were more likely to initiate ART
at an older age with lower baseline CD4 levels and more
advancedWHOstaging[36,37].Inaddition,unemployment
of the caregiver and high travel costs were risk factors for
late disease stage at presentation in quantitative analysis.
The qualitative interviews in our study conﬁrmed these
socioeconomic factors as important barriers, especially in
the smaller towns. Prior studies from Uganda and other
resource-limited settings have reported similar ﬁndings,
suggesting that interventions such as community outreach,
transportation refunds, home-based ART distribution, or
outreach clinics in orphanages might be useful in overcom-
ing these issues [38–42].
Other personal factors observed in the interviews were
caregivers’ unawareness of HIV symptoms, stigma, and fear,
conﬁrming that these personal beliefs discourage people
from seeking ART [10, 22]. In addition to lack of knowl-
edge of HIV symptoms, unawareness of free HIV services
also impedes timely presentation [43]. Media campaigns
designed to inform people about ANC, HIV testing, and free
ART for children could be improved at relatively low cost
[44, 45].
One of this study’s strengths was the mixedmethod
approach by which quantitative data could be contextu-
alized and conﬁrmed by qualitative study. Methodological
triangulation increased the credibility of the ﬁndings and
enhanced comprehensiveness of the study, creating a deeper
understanding of the barriers to initiation of pediatric HIV
care [46–49]. A limitation of the study is the cross-sectional
design, making it diﬃcult to establish causal relations in the
quantitative analysis. In the qualitative study, there is a risk
of socially desirable answers during the interviews.
Finally, diﬀerent types of selection bias may have aﬀected
our study. First, late disease stage at presentation could have
been overestimated as many children were referred to JCRC
after visiting other clinics; the disease stage at presentation
in the referring clinics was not part of our study. Second,
our study did not take into account the HIV-infected chil-
dren that died before reaching the clinic. As the median age
was over 4 years old in our cohort, this population con-
sisted of mostly medium and slow progressors. Younger
children appeared to be a risk factor for late disease stage at
presentation but this ﬁnding is subject to survival bias and
should be interpreted accordingly. Additionally, other risk
factors identiﬁed might not apply to children with fast
disease progression. The speciﬁc barriers experienced by
these children and their caregivers should be evaluated in
longitudinal studies of HIV-exposed children.
Inconclusion,althoughﬁrst-lineARThasbecomewidely
available for HIV-infected children in Uganda, this alone
does not ensure timely access. The problem of late disease
stage at presentation requires a multifactorial approach, pri-
oritizingcommunityandorphanageoutreachprograms,and
linkage of ANC systems to ART providers. Knowledge of
these factors and their potential solutions is important in
order to help health workers and ART program planners to
create interventions to reach HIV-infected infants as early as
possible and avoid preventable child mortality.
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